Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Affiliations

• ¹ Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
• ² Kite Pharma, Santa Monica, CA, USA.
• ³ Medical Oncology/Hematology Fellowship Program, NCI, Bethesda, MD, USA.
• ⁴ Lymphoid Malignancy Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
• ⁵ Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
• ⁶ Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
• ⁷ Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁸ Office of Regulatory Affairs, NCI, NIH, Bethesda, MD, USA.
• ⁹ Center for Cellular Engineering, Clinical Center, NIH, Bethesda, MD, USA.
• ¹⁰ Surgery Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
• ¹¹ Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. [email protected].